Contribute Try STAT+ Today

“What we make here is cells.”

With crews still finishing electrical work and bulky lab equipment sitting ready for use, Dr. Jerome Ritz gave a tour this week of Dana-Farber Cancer Institute’s new, 30,000-square-foot cell manufacturing facility on the 12th floor of one of the hospital’s Boston buildings. It’s a factory of sorts, but one producing the potential medicines of the future, when treatments will be whipped up by editing DNA in cells that are then reintroduced into patients (some of these are already on the market) or even by converting one type of cell into another kind.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.